NCT03831932 2025-09-19Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung CancerNational Cancer Institute (NCI)Phase 1/2 Active not recruiting22 enrolled 12 charts